- Medical Devices also were amongst the best performers – Smith & Nephew up 1.8%.
- All 9 subthemes suffered strong declines – lead by Telemedicine and Gene Sequencing – both down over -25 %.
- WELL’s returns are driven by Medical Device holdings (29.6% weight), Biotech (26.9%), Genome Sequencing (13.5%), Neuroscience (9.9%) & Telemedicine (6.4%).
- Holdings are increasingly global – US 67.9%, Japan 8.4%, China 5.7%, Switzerland 3.1% and Netherlands 2.1%. [1]
- Hospitals continue to embrace Cloud computing boom – boosting Telemedicine, Wearables, Healthcare Data adoption. [2]
- Big Tech acquisitions of Healthcare Analytics companies - boosting digitalization across Healthcare sector.
Macro Outlook:
- The Global Health Wearables market is projected to grow significantly – with medical sensors/devices approaching a 20% compound annual growth rate by 2024.[3] Fitness Trackers and Smartwatches are likely to grow at a slower rate.
- Big Tech is increasingly active across the Healthcare Innovation space - expect more Big Tech deals following the Oracle’s $30bn Cerner digital data deal (electronic medical records). [4]
- Digitalization across healthcare space could be fast tracked by M&A deals. [5]
- High inflation and rising interest rates hurting valuations – worst impacted were Gene Sequencing and Telemedicine holdings.
- US midterm elections likely to see Republicans retake Congress. This would suggest the adoption of a more business-friendly approach to Healthcare Deals/M&A.[6] (See recent Oracle and Microsoft deals below).
- If the US Fed tames inflation and rates top out – we expect valuations to recover.
- Growing hospital use of Cloud Computing during the Pandemic – embracing Telemedicine and Wearables. [7]
- We observe that healthcare is highly fragmented and labour intensive industry which makes it ripe for Tech Innovation/Disruption.
- With the US baby-boomer generating aging into their 70s and 80s, it is expected that there will be increased healthcare demand.
- Oracle’s purchase of Cerner serving doctors/patients ($30bn), Microsoft’s $26bn Nuance Communications acquisition & Google Cloud’s digitalization deal with one of the largest US hospital groups (HCA Healthcare 2000+ locations) – highlights increasing Tech adoption. [8]
|
Contribution to Return
|
|
Sub-Themes
|
YTD
|
April
|
|
Telemedicine
|
-35.73%
|
-26.86%
|
|
Genome Sequencing
|
-51.87%
|
-26.21%
|
|
Medical Devices
|
-21.04%
|
-13.36%
|
|
Neuroscience
|
-25.16%
|
-18.22%
|
|
Bioinformatics
|
-36.80%
|
-22.21%
|
|
Biological Engineering
|
-21.58%
|
-12.30%
|
|
Healthcare Analytics
|
-42.67%
|
-20.29%
|
|
Robotics
|
-26.23%
|
-18.85%
|
|
Healthcare Trackers
|
-23.63%
|
-18.81%
|
Past performance is no guarantee of future performance. Please note that all performance figures are showing net data. Source: INDXX. Data as of 30.04.2022
|
Company Name
|
Sub-Themes
|
April (Contribution to Return)
|
|
ALKERMES PLC
|
Biological Engineering
|
0.39%
|
|
BIOCON LTD
|
Biological Engineering
|
0.37%
|
|
BIOMARIN PHARMACEUTICAL INC
|
Biological Engineering
|
0.22%
|
|
JAZZ PHARMACEUTICALS INC
|
Biological Engineering
|
0.12%
|
|
SMITH AND NEPHEW PLC
|
Medical Devices
|
0.07%
|
|
SHANDONG WIEGO GROUP MEDICAL CO LTD
|
Medical Devices
|
0.01%
|
| IONIS PHARMACEUTICALS INC |
Biological Engineering
|
-0.03%
|
|
ZIMVIE INC
|
Medical Devices
|
-0.06%
|
|
COCHLEAR LTD
|
Medical Devices
|
-0.10%
|
|
DEMANY A/S
|
Medical Devices
|
-0.12%
|
Past performance is no guarantee of future performance. Please note that all performance figures are showing net data. Source: INDXX. Data as of 31.04.2022
HAN-GINS Indxx Healthcare Innovation UCITS ETF – Performance (As of 30.04.22)
|
|
1M
|
3M
|
6M
|
YTD
|
12M
|
2Y
|
3Y
|
SI
|
|
HAN-GINS Indxx Healthcare Megatrend
|
-15.94%
|
-17.79%
|
-35.72%
|
-29.80%
|
-36.37%
|
-13.71%
|
-4.52
|
-7.04%
|
|
Indxx Global NextGen Healthcare Index (NTR)
|
-15.82%
|
-17.69%
|
-35.49%
|
-29.65%
|
-36.26%
|
-13.17%
|
-3.03%
|
-5.55%
|
Past performance for the index is in USD. Past performance is not an indicator for future results and should not be the sole factor of consideration when selecting a product. Investors should read the prospectus of the Issuer (“Prospectus”) before investing and should refer to the section of the Prospectus entitled ‘Risk Factors’ for further details of risks associated with an investment in this product. Source: Bloomberg / HANetf. Data as of 30.04.2022. Please note that all performance figures are showing net data.
Learn more about our healthcare innovation ETF here.